In this Contract Pharma webinar on May 19th, sponsored by Marken, explore strategies for resilient healthcare supply chains, from cold chain logistics to real-time visibility and global risk mitigation.
Biopharma companies face a complex journey as they strive to transform groundbreaking ideas into life-saving therapeutics. The process is fraught with challenges, also driven by current geopolitical changes. This playbook explores how CDMOs can help.
New offering aims to help biotech and pharma companies move lentiviral vector programs from research into clinical-grade manufacturing with lower development risk, faster timelines and greater regulatory readiness.
Vetter is a leading and independent global CDMO for the aseptic production of injectables. Its roots and headquarters are in Ravensburg, Germany. Vetter has been a stable, reliable family-owned company since its establishment as a pharmacy in 1950, now with more than 7,400 skilled and dedicated employees.
We are a leading provider of high-quality small-molecule APIs and pharmaceutical intermediates. With over 55 years of expertise and a proven track record in developing numerous new chemical entity (NCE) products across diverse therapeutic areas, we have established ourselves as a trusted partner for innovative pharmaceutical companies worldwide.
